Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
PRED-G is an ophthalmic suspension approved in 1988 for eye-related indications delivered as topical drops. The exact mechanism of action and indication are not publicly detailed in available data, but the product is a small-molecule formulation typical of legacy ophthalmology treatments. PRED-G is a mature branded product facing loss of exclusivity.
With LOE approaching and moderate competitive pressure (30/100), the brand team is likely focused on defending market share and managing transition to generic or authorized generic strategies.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
PRED-G offers limited career growth opportunity as a legacy product approaching LOE with zero linked job openings. Career value lies in executing defensive commercial strategies, managing payer relationships, and potentially transitioning the product to a lower-cost business model post-exclusivity.
Worked on PRED-G at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.